1. Serum Preptin and Amylin Values in Psoriasis Vulgaris and Behçet's Patients.
- Author
-
Dogan FB, Cicek D, Aydin S, Dertlioglu SB, Halisdemir N, Ucak H, Demir B, and Erden I
- Subjects
- Adult, Case-Control Studies, Humans, Insulin-Like Growth Factor II, Behcet Syndrome blood, Islet Amyloid Polypeptide blood, Peptide Fragments blood, Psoriasis blood
- Abstract
Background: Insulin resistance is found in both psoriasis and Behçet's disease. No study has yet explored whether preptin and amylin, two hormones associated with insulin resistance, are involved in the insulin resistance observed in patients with psoriasis and Behçet's disease., Objectives: We aimed to explore how the amounts of preptin and amylin change in psoriasis and Behçet's disease and whether they are involved in the etiopathology of these two diseases, by comparing hormone levels in patients and healthy controls., Methods: The study registered 30 patients with psoriasis, 30 patients with Behçet's disease, and 30 healthy volunteers (as a control group). Fasting blood sugar, triglyceride, LDL, VLDL, HDL, total cholesterol, HbA1c, C-peptide, insulin, and serum preptin and amylin levels were measured in all subjects., Results: Serum preptin and amylin levels were significantly lower in the patients with psoriasis and Behçet's disease than in the control group (P < 0.001, P = 0.004, and P = 0.008, respectively). A comparison of the serum preptin and amylin levels between the patients with psoriasis and Behçet's disease did not reveal a statistically significant difference. Serum insulin level and The homeostasis model assessment of insulin resistance (HOMA-IR) index were significantly lower in the psoriasis patient group relative to the control group (P = 0.02 and P = 0.03, respectively), while the values for the Behçet's disease group did not differ significantly from those for the control group, Conclusions: Serum levels of preptin and amylin were significantly lower in patients with psoriasis and Behçet's disease, indicating that these hormones may be a factor for development of metabolic syndrome in these two diseases., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF